

Preserving Fertility in Rheumatologic Disease

BY DIANA MAHONEY
New England Bureau

CHICAGO — Fertility preservation options should be presented to patients as early after the diagnosis of rheumatoid arthritis, systemic lupus erythematosus, and scleroderma as possible.

These rheumatologic diseases often strike both men and women during their childbearing years, and the diseases themselves as well as the long-term therapies used to treat them can have a negative impact on reproductive health.

"It's important to recognize that [while] many of the innovative technologies available today to treat life-threatening diseases and to provide patients with the promise of life after their disease, whether it be cancer, rheumatic disease, or other type of life-threatening condition ... many of these drug treatments can be devastating in terms of reproductive health," according to Marybeth Gerrity, Ph.D., executive director of the Oncofertility Consortium at Northwestern University, Chicago.

"While many of us who treat patients with chronic diseases sometimes have a tendency to think in terms of, 'That's the least of your worries,' it's increasingly be-

coming a concern of survivors to look at these sorts of quality of life issues and so we need to change our mind set," she said at a symposium sponsored by the American College of Rheumatology.

In order to effect this change, it's important not only to consider the pharmacology and reproductive impact of the drugs being used to treat rheumatologic diseases, but also to have a heightened awareness of the types of standard fertility preservation options, "so you can at least have your receptors retuned to some of the things that may be appropriate for your patients," Dr. Gerrity said.

The list of drugs used to manage and treat rheumatic diseases that are known to affect reproductive health include, but may not be limited to, cyclophosphamide, chlorambucil, nonsteroidal anti-inflammatory drugs (NSAIDs), sulfasalazine, methotrexate, and leflunomide, she said.

With respect to cyclophosphamide treatment for lupus nephritis, for example, while the cytotoxic-induced damage is reversible in some tissues of rapidly dividing cells, the damage to the ovary, with its limited number of germ cells, tends to be progressive and irreversible, she said, noting that, "in studies, up to 70% of adult female

patients taking daily oral cyclophosphamide and nearly half of those receiving a monthly intravenous pulse developed amenorrhea and experienced permanent ovarian failure within a year of first dose."

The alkylating agent chlorambucil has been shown to affect both male and female fertility. "Studies have shown that adult and adolescent women taking chlorambucil exhibit an increased rate of ovarian failure," Dr. Gerrity said. "[The drug] may cause an arrest in follicular maturation, stromal fibrosis, and a decreased number of ova in the ovary, leading to delayed onset of menstruation and amenorrhea."

In adolescent and adult male patients, chlorambucil, either alone or in combination with prednisone or azathioprine, has been linked to temporary azoospermia.

"This may be due to inhibition of DNA synthesis in developing sperm and damage to the cells of the seminiferous epithelium," noted Dr. Gerrity.

Male patients taking sulfasalazine, methotrexate, cyclophosphamide, and leflunomide may also face the risk of oligospermia and impaired sperm motility, while women taking NSAIDs may have trouble conceiving because the drugs can inhibit blastocyst implantation, Dr. Gerrity said.

Among the "routine" fertility preservation options available to patients, Dr. Gerrity explained, are sperm banking, testicular tissue banking, GnRH analogs or antagonists, and donor sperm for men and embryo or egg banking and emergency in vitro fertilization, ovarian tissue cryopreservation, donor eggs, and gestational carriers for women.

"Embryo banking and in vitro fertilization are routine in the infertility clinic and involve stimulating women with high doses of fertility drugs to cause them to produce a lot of eggs that can be fertilized in the laboratory to produce embryos that can then be stored for later implantation."

However, there are drawbacks to this option: "It's expensive, and it requires at least 3 weeks of preparation and treatment before egg retrieval, which may not be medically reasonable for some patients," she said.

Another roadblock, until recently, was the fact that banking of eggs had been technologically impossible, and banking of embryos required a sperm source. "For some people without a partner, facing a life-threatening disease or long-term therapy that would impair their fertility, the prospect of undergoing a \$12,000 procedure to retrieve eggs and then having to pick the man of their dreams out of a catalog is an overwhelming prospect," Dr. Gerrity said.

Fortunately, thanks to a "political fluke" in Europe, there have been tremendous advances within the last year, leading to the ability to successfully freeze eggs for later fertilization.

"About 2 years ago, the Italian government made the freezing of human em-

bryos illegal in that country, meaning that all of the patients in Italy undergoing [in vitro fertilization] could only add sperm to eggs that could safely be returned to their uterus—usually two to three eggs," Dr. Gerrity explained.

Faced with the prospect of having to waste the majority of eggs retrieved from patients, "the Italian scientists kicked into gear and solved the problem we've been working on for more than 20 years: They broke the code on how to freeze eggs, so now frozen eggs yield the same pregnancy and fertilization rates as fresh eggs," she said. "For the patients needing to bank eggs before starting fertility-impairing drug treatment, at least they don't also have to select a sperm donor on the spot."

Although the success rates associated with frozen egg fertilization are high, the technology is still considered investigational in the United States, "which of course is an issue when dealing with third-party payers."

A new frontier for fertility preservation in women is ovarian tissue cryopreservation, whereby portions of the ovary or the entire ovary are removed and the cortical tissue is frozen and later reimplanted into the patient.

"This is a technique that we are using extensively in young girls and prepubertal girls with cancer and in patients who have to begin so quickly that taking 3 weeks out to stimulate ovaries is just not possible," said Dr. Gerrity. "Although the freezing of the tissue is simple, the challenge has been in 'waking it up' once it's reimplanted. This has been the focus of research over the last 2-3 years, and it has paid off. In the past 6 months, there have been reports of about 14 pregnancies with transplanted ovarian tissue following chronic treatment or chemotherapy."

Upon implantation, all of the women began menstrual cycling again and became pregnant spontaneously, she said. This technique is only an option for those patients who can be withdrawn from their fertility-compromising drugs or drugs that are contraindicated in pregnancy for the period of conception and gestation, she added.

For patients who cannot carry a pregnancy because it would be unsafe or unwise to withdraw from therapy, "gestational carriers may be the best option," said Dr. Gerrity. "Unlike true surrogates, who lend their eggs and their uterus, gestational surrogates just lend their uterus to the effort, carrying to term the fertilized embryos from the patient and her partner."

In order to determine the best fertility preservation option for an individual patient, "it's important to have the patient sit down with a reproductive endocrinologist," Dr. Gerrity stressed. "As the part of this process, it's critical that [the referring physician] keeps an open line of communication with the reproductive endocrinologist. Be clear about what you can do in terms of treatment," she said. ■

In the technique of ovarian tissue cryopreservation, portions of the ovary or the entire ovary are removed and the cortical tissue is frozen and later reimplanted.

DUET®DHA^{ec} by StuartNatal®

Rx Only

DESCRIPTION: Duet®DHA^{ec} is a prescription regimen of prenatal multi-vitamin, multi-mineral, and omega-3 fatty acid supplements, supplied as tablets and enteric-coated softgel capsules.

Each yellow oval Duet® Tablet* contains:

VITAMINS	
A (beta carotene)	3,000 IU
C (ascorbic acid)	120 mg
D (cholecalciferol)	400 IU
E (dl-alpha tocopheryl acetate)	3 mg
B ₁ (thiamine mononitrate)	1.8 mg
B ₂ (riboflavin)	4 mg
Niacinamide	20 mg
B ₆ (pyridoxine hydrochloride)	25 mg
Folic acid	1 mg
B ₁₂ (cyanocobalamin)	12 mcg
MINERALS	
Calcium (calcium carbonate)	200 mg
Iron (ferrous bisglycinate HCl and IronAid® ¹)	29 mg
Magnesium (magnesium oxide)	25 mg
Zinc (zinc oxide)	25 mg
Copper (cupric oxide)	2 mg

Each frosted golden-colored oval enteric-coated DHA softgel capsule* contains:

400 mg purified omega-3 fatty acids including: At least 275 mg DHA (docosahexaenoic acid); also contains EPA (eicosapentaenoic acid) and other omega-3 fatty acids.

OTHER INGREDIENTS (Duet® Tablet): Acacia, ascorbyl palmitate, butylated hydroxytoluene, casein, cornstarch, croscarmellose sodium, dicalcium phosphate, dl-alpha tocopherol, gelatin, hypromellose, magnesium stearate, microcrystalline cellulose, mixed glycerides, polyethylene glycol, polysorbate 80, silicon dioxide, sodium aluminum silicate, sodium ascorbate, sodium benzoate, sorbic acid, sucrose, titanium dioxide.

OTHER INGREDIENTS (Enteric-coated DHA softgel capsule): Ammonium hydroxide, ethylcellulose, fractionated coconut oil, gelatin, glycerin, oleic acid, stearic acid, sodium alginate and DHA and EPA concentrate derived from purified fish oil via a proprietary process.

*USP Compliance: Duet® Tablet is formulated in conformance with official U.S. Pharmacopeia (USP) standards of quality for potency, purity and dissolution. The enteric-coated DHA softgel capsule complies with the standards and methods outlined in the CRN Voluntary Monograph for potency and purity.

INDICATIONS: Duet®DHA^{ec} is a prescription regimen of prenatal multi-vitamin, multi-mineral, and omega-3 fatty acid supplements indicated for use in improving the nutritional status of women throughout pregnancy and in the post-natal period for both lactating and non-lactating mothers. Duet®DHA^{ec} is also useful in improving nutritional status prior to conception.

CONTRAINDICATIONS: This product is contraindicated in patients with known hypersensitivity to any of the ingredients including fish or fish oil.

WARNINGS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B₁₂ is deficient.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or a poison control center immediately.

Since daily ingestion of more than 3 grams per day of omega-3 fatty acids (including alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)) from fish oils may have potential antithrombotic activities and may increase bleeding times, administration of DHA should be avoided in patients with inherited or acquired bleeding diatheses, including those taking anticoagulants.

PRECAUTIONS: Folic acid in doses above 0.1 mg daily may obscure the diagnosis of pernicious anemia (hematologic remission may occur while neurological manifestations remain progressive).

DRUG INTERACTIONS: Pyridoxine supplements should be avoided in patients receiving levodopa alone, as the actions of levodopa may be antagonized.

ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSAGE AND ADMINISTRATION: Before, during and after pregnancy, one tablet and one enteric-coated softgel capsule taken by mouth daily, or as directed by a physician. The tablet and enteric-coated softgel capsule may be taken together or at different times of the day. Caution should be exercised to ensure that the prescribed dose of DHA does not exceed 1 gram (1,000 mg) per day.

HOW SUPPLIED: NDC 66479-861-30. Duet®DHA^{ec} is supplied in child-resistant, unit-dose blister cards containing 6 Duet® tablets and 6 enteric-coated DHA softgel capsules per card. Each unit-of-use dispensing carton contains 5 unit-dose cards which is a 30-day supply. Duet® is a yellow oval tablet imprinted with the StuartNatal® logo ("heart-in-a-heart") on one side and "858" on the other. The frosted golden-colored oval enteric-coated DHA softgel capsule is imprinted with the StuartNatal® logo ("heart-in-a-heart" outlined traced).

STORAGE: Store at controlled room temperature 20–25°C (68–77°F). Protect from moisture and excessive heat. Note that contact with moisture may produce surface discoloration of the tablet.

DISPENSING: Keep in a well-closed, light-resistant container as defined by the USP. Unit dose blisters are child-resistant to opening, as a safeguard against ingestion by children. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Questions or Comments: 1-877-926-6396
www.DuetDHA.com

Marketed by:
Xanodyne
pharmaceuticals, inc.
Newport, KY 41071, USA

StuartNatal, Duet and the "heart-in-a-heart" logo are registered trademarks of Xanodyne Pharmaceuticals, Inc. Patents pending. All rights reserved.

¹ IronAid is a registered trademark of Chemi Nutra.

© 2007, Xanodyne® Pharmaceuticals, Inc.

PI-861-A Revision 08/07

LC-10705